top of page

The Estrella Approach

Anchor 1

53%

5-year overall survival (OS)

6

NHL has the sixth highest mortality rate among cancers in the US

th

NHL patients with relapsed/refractory (R/R) aggressive B-cell NHLs have a poor prognosis:

female-patients-talking-hospital.jpg
female-patients-talking-hospital (1).jpg

Unmet Medical Needs in NHL

CAR-T (Chimeric Antigen Receptor T cell) therapies represent a new class of cancer immunotherapy that harnesses your own immune system to fight cancer. The initial class of CAR T has shown remarkable efficacy in certain types of blood cancers. However, its life-threatening side effects, such as Cytokine Release Syndrome (CRS) and neurotoxicity remain a challenge in allowing more patients to access such therapies.

Furthermore, patients with particularly challenging R/R B-cell NHLs, such as human immunodeficiency virus (HIV)-associated lymphoma, central nervous system (CNS) lymphoma, and additional high-grade NHL subtypes have traditionally been excluded in clinical trials and therefore the labeling of current FDA approved CAR-T therapies. 

Estrella's unique advantage - ARTEMIS T Cells

Designed as a next-generation T-cell immunotherapy, ARTEMIS T cells are redirected by an antibody-T-cell-receptor (AbTCR) to specifically go after CD19, a protein found on the surface of malignant B cells.

Once infused into patient's body, the binding domains of the AbTCR and co-stimulatory molecule will seek out and bind to CD19 targets, activating ARTEMIS T cells to recognize and kill the target cancer cell. ARTEMIS T cells are designed to resemble one's natural immune system, minimizing the risks of side effects caused by T-cell mediated toxicity, such as CRS and neurotoxicity.

Source-Unmet Medical Needs
bottom of page